-
ALSO READ
Aurobindo Pharma arm gets 2 observations from USFDA
Aurobindo Pharma arm gets USFDA nod for fungal infection drug
Aurobindo Pharma gets Form 483 with 10 observations from USFDA
Aurobindo Pharma's step-down subsidiary to commercialize Ryzneuta in the United States
Auropharma's API facility gets EIR from USFDA
-
The US Food Drug and Administration (USFDA) concluded that the inspection classification of Aurobindo Pharma's wholly owned subsidiary, APL Healthcare's facility of telangana is Volunatry Action Indicated (VAI).
Earlier on 18 January 2023, the drug regulator had inspected the Unit I & III, an Orals (tablets, capsules and soft gel capsules) and Derma manufacturing facility located at Jadcherla, Mahabub Nagar District, Telangana, from 9 January 2023 to 18 January 2023 and issued form 483 with 2 observations.Aurobindo Pharma develops, manufactures and distributes generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients.
The company's consolidated net profit declined 18.8% to Rs 491.26 crore despite of 6.7% rise in net sales to Rs 6,387.97 crore in Q3 FY23 over Q3 FY22.
The scrip rose 0.40% to Rs 475.75 on the BSE.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Subscribe to Business Standard Premium
Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!
Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.
Download the Business Standard App for latest Business News and Market News .
RECOMMENDED FOR YOU